AI-generated summary
The authors reviewed two randomized trials, from the UK and Canada, comparing photobiomodulation with sham treatment, no treatment or standard care in people with non-exudative age-related macular degeneration. They report no clear difference in best-corrected visual acuity at 12 months and inconclusive evidence on whether the therapy slows disease progression. The authors state the certainty of the evidence is low and that further well-designed controlled trials are needed.
- Participants
- 90
- Studies included
- 2
- Who or what was studied
- People with non-exudative age-related macular degeneration (AREDS categories 2 to 4)
- Limits stated in the abstract
- The review includes only two small single-centre trials with low or very low certainty evidence, and the authors note risk of performance and attrition bias.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on doi.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Age-related macular degeneration, Photobiomodulation, Sham, Wavelength, Randomized controlled trial, Confidence interval, Attrition, Dosimetry. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.